The clinical trial application of ST-1898, a class 1 small molecule drug with global independent intellectual property rights of Beijing Scitech Pharmaceutical Technology Co., Ltd (Scitech Pharma), was officially accepted by the Drug Review Center of the National Medical Products Administration on May 8, 2020.

ST-1898 is developed by Scitech Pharma and is intended for the treatment of solid tumors. It is a multi-target tyrosine kinase inhibitor, and the results of preclinical trials have shown that ST-1898 significantly inhibits tumor growth in several tumor efficacy models in mice (including CDX/PDX models of liver cancer, lung cancer, gastric cancer and intestinal cancer). Since ST-1898 can effectively inhibit several tyrosine kinases that are closely related to tumorigenesis, it has a wide range of applications for various indications and is expected to provide new therapeutic treatments for cancer patients and benefit human health.